MedTrace Logo

A Study in Healthy People to Test Whether BI 1291583 Influences the Amount of Dabigatran in the Body

NCT06791187 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2025-08-13

No results posted yet for this study

Summary

The main objective of this trial is to investigate the effect of a single dose of BI 1291583 on the pharmacokinetics of a single dose of dabigatran, an efflux transporter P-glycoprotein (P-gp) substrate.

Conditions

  • Healthy

Interventions

DRUG

dabigatran etexilate

dabigatran etexilate

DRUG

BI 1291583

BI 1291583

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-23
Primary Completion
2025-02-21
Completion
2025-03-27

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06791187 on ClinicalTrials.gov